BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 11840263)

  • 1. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
    Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
    Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia].
    Martinet D; Mühlematter D; Jotterand Bellomo M
    Schweiz Med Wochenschr; 1996 May; 126(20):855-63. PubMed ID: 8685681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
    Yanagi M; Shinjo K; Takeshita A; Tobita T; Yano K; Kobayashi M; Terasaki H; Naoe T; Ohnishi K; Ohno R
    Leukemia; 1999 Apr; 13(4):542-52. PubMed ID: 10214860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
    Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
    Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
    Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
    Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic diagnosis of chronic myeloid leukemia].
    Kato C; Naoe T
    Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
    Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
    Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
    Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
    Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
    Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
    Am J Hematol; 2012 Aug; 87(8):760-5. PubMed ID: 22641468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.